- Celexa and Prednisone drug interactions, a phase IV clinical study of FDA data - eHealthMe
Looking for:
Citalopram (Celexa) - Side Effects, Interactions, Uses, Dosage, Warnings | Everyday Health |
Citalopram (Oral Route) Precautions - Mayo Clinic - User Reviews & Rating
People with depression or mental illness may have thoughts about suicide. Some young people may have increased suicidal thoughts when first starting a medicine to treat depression. Stay alert to changes in your mood or symptoms. Your family or caregivers should also watch for sudden changes in your behavior.
Taking this medicine during pregnancy could harm the baby, but stopping the medicine may not be safe for you. Do not start or stop citalopram without asking your doctor. Get emergency medical help if you have signs of an allergic reaction: hives, rash, blisters; fever, joint pain; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your doctor right away if you have new or sudden changes in mood or behavior, including new or worse depression or anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, more active or talkative, or have thoughts about suicide or hurting yourself.
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired. Use Citalopram Celexa exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Your doctor may occasionally change your dose. Use the medicine exactly as directed. Tell your doctor if you have any changes in sexual function, such as loss of interest in sex, trouble having an orgasm, or in men problems with erections or ejaculation. Some sexual problems can be treated.
Prednisolone is predicted to decrease the efficacy of Atezolizumab. Manufacturer advises use with caution or avoid.
Prednisolone is predicted to decrease the effects of Atracurium. Both Prednisolone and Bambuterol can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Bedaquiline.
Both Prednisolone and Bendroflumethiazide can increase the risk of hypokalaemia. Benzydamine increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Bosutinib. Bromfenac increases the risk of gastrointestinal bleeding when given with Prednisolone. Both Prednisolone and Bumetanide can increase the risk of hypokalaemia.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Cabozantinib. Carbamazepine is predicted to decrease the exposure to Prednisolone. Celecoxib increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Ceritinib.
Both Prednisolone and Chlorothiazide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Chlorpromazine. Both Prednisolone and Chlortalidone can increase the risk of hypokalaemia. Prednisolone is predicted to decrease the concentration of Choline salicylate. Prednisolone is predicted to decrease the effects of Cisatracurium. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Citalopram.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Clarithromycin. Clarithromycin is predicted to increase the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Clomipramine.
Cobicistat is predicted to increase the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Crizotinib.
Darunavir is predicted to increase the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Dasatinib. Prednisolone is predicted to increase the risk of gastrointestinal bleeding when given with Deferasirox.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Delamanid. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Desflurane.
Dexketoprofen increases the risk of gastrointestinal bleeding when given with Prednisolone. Diclofenac increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to increase the risk of Digoxin toxicity when given with Digoxin. Prednisolone is predicted to increase the risk of immunosuppression when given with Dinutuximab. Manufacturer advises avoid except in life-threatening situations. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Disopyramide.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Dronedarone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Droperidol. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Efavirenz.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Encorafenib. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Entrectinib.
Enzalutamide is predicted to decrease the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Eribulin. Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Erythromycin. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Escitalopram. Etodolac increases the risk of gastrointestinal bleeding when given with Prednisolone. Etoricoxib increases the risk of gastrointestinal bleeding when given with Prednisolone. Felbinac increases the risk of gastrointestinal bleeding when given with Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Flecainide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Fluconazole. Flurbiprofen increases the risk of gastrointestinal bleeding when given with Prednisolone.
Both Prednisolone and Formoterol can increase the risk of hypokalaemia. Fosamprenavir is predicted to increase the exposure to Prednisolone. Fosphenytoin is predicted to decrease the exposure to Prednisolone.
Both Prednisolone and Furosemide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Glasdegib.
Prednisolone potentially opposes the effects of Glycerol phenylbutyrate. Manufacturer advises monitor ammonia concentrations. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Haloperidol. Herpes-zoster vaccine, live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose.
Both Prednisolone and Hydrochlorothiazide can increase the risk of hypokalaemia. Both Prednisolone and Hydroflumethiazide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxychloroquine.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxyzine. Ibuprofen increases the risk of gastrointestinal bleeding when given with Prednisolone. Idelalisib is predicted to increase the exposure to Prednisolone.
Both Prednisolone and Indacaterol can increase the risk of hypokalaemia. Drug interactions are reported among people who take Celexa and Prednisone. Common interactions include drug ineffective among females and pain among males. The phase IV clinical study analyzes what interactions people who take Celexa and Prednisone have.
You can use the study as a second opinion to make health care decisions. With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. Prednisone has active ingredients of prednisone. It is often used in rheumatoid arthritis. You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
❿Citalopram is selective serotonin reuptake inhibitor SSRI antidepressant. Citalopram may also be used for purposes not listed in this medication guide. You should not use this medicine if you are allergic to citalopram or escitalopram Lexaproor if you also take pimozide. Do not use citalopram within 2 weeks before or after using an MAO inhibitor in the past 14 days. A dangerous drug interaction could occur. MAO inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, and tranylcypromine.
Tell your doctor if you also use stimulant medicine, opioid medicine, herbal products, or medicine for depression, mental illness, Parkinson's disease, migraine headaches, serious infections, or prevention of nausea and vomiting. An interaction with citalopram could cause a serious condition called serotonin syndrome. People with depression or mental illness may have thoughts about suicide. Some young people may have increased suicidal thoughts when first starting a medicine to treat depression.
Stay alert to changes in your mood or symptoms. Your family or caregivers should also watch for sudden changes in your behavior. Taking this medicine during pregnancy could harm the baby, but stopping the medicine may not be safe for you. Do not start or stop citalopram without asking your doctor.
Get emergency medical help if you have signs of an allergic reaction: hives, rash, blisters; fever, joint pain; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your doctor right away if you have new or sudden changes in mood or behavior, including new or worse depression or anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, more active or talkative, or have thoughts about suicide or hurting yourself.
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.
Use Citalopram Celexa exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose. Use the medicine exactly as directed.
Tell your doctor if you have any changes in sexual function, such as loss of interest in sex, trouble having an orgasm, or in men problems with erections or ejaculation. Some sexual problems can be treated. If you stop using citalopram suddenlyyou may have unpleasant symptoms such as agitation, confusion, tingling or electric shock feelings.
Ask your doctor before stopping the medicine. Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time. Health Conditions A-Z. Health Tools. See All.
DailyOM Courses. Citalopram Celexa. Brand Names: CeleXA. Reviewed: November 9, Citalopram is used to treat depression. Tell your doctor if you have ever had: heart problems; long QT syndrome in you or a family member ; high blood pressure; a stroke; bleeding problems; sexual problems; liver or kidney disease; narrow-angle glaucoma; seizures or epilepsy; bipolar disorder manic depression ; or an electrolyte imbalance such as low levels of potassium, magnesium, or sodium in your blood.
You should not breastfeed. Not approved for use by anyone younger than 18 years old. Side Effects. Side Effects What are the side effects of Citalopram Celexa?
Call your doctor at once if you have: a light-headed feeling, like you might pass out; blurred vision, eye pain or redness, seeing halos around lights; fast or pounding heartbeats, pain or fluttering in your chest, shortness of breath, and sudden dizziness like you might pass out ; a seizure; manic episodes --racing thoughts, increased energy, decreased need for sleep, risk-taking behavior, being agitated or talkative; severe nervous system reaction --very stiff rigid muscles, high fever, sweating, confusion, fast or uneven heartbeats, tremors; or low blood sodium --headache, confusion, problems with thinking or memory, weakness, feeling unsteady.
Common side effects may include: sexual problems; dizziness, drowsiness; dry mouth, thirst, increased sweating or urination; loss of appetite, nausea, diarrhea, constipation; feeling anxious, agitated, or shaky; feeling weak or tired; sleep problems insomnia ; yawning; increased muscle movement; nosebleeds, heavy menstrual bleeding; or cold symptoms such as stuffy nose, sneezing, sore throat.
Based on FDA pregnancy categories. Interactions What drugs and food should I avoid while taking Citalopram Celexa? Avoid drinking alcohol. Measure liquid medicine with the supplied measuring device not a kitchen spoon. Your symptoms may not improve for up to 4 weeks. Store at room temperature away from moisture and heat.
What should I do if I missed a dose of Citalopram Celexa? If you think you or someone else may have overdosed on: Citalopram Celexacall your doctor or the Poison Control center. If someone collapses or isn't breathing after taking Citalopram Celexacall A, 05 Color : orange Shape : round Imprint : A, A, 0 6 Color : pink Shape : capsule Imprint : A, 0 6. See More. Medical Disclaimer Drugs A-Z provides drug information from Everyday Health and our partners, as well as ratings from our members, all in one place.
The information within all other sections is proprietary to Everyday Health. Read more.
❾-50%}Prednisone interactions with celexa -
The use of the eHealthMe site and its content is at your own risk. If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date. All rights reserved. Use of this site constitutes acceptance of eHealthMe. Toggle navigation eHealth Me. Home Analysis Celexa Prednisone. What is Celexa? Get emergency medical help if you have signs of an allergic reaction: hives, rash, blisters; fever, joint pain; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your doctor right away if you have new or sudden changes in mood or behavior, including new or worse depression or anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, more active or talkative, or have thoughts about suicide or hurting yourself.
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired. Use Citalopram Celexa exactly as directed on the label, or as prescribed by your doctor.
Do not use in larger or smaller amounts or for longer than recommended. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Your doctor may occasionally change your dose. Use the medicine exactly as directed. Tell your doctor if you have any changes in sexual function, such as loss of interest in sex, trouble having an orgasm, or in men problems with erections or ejaculation. Some sexual problems can be treated. If you stop using citalopram suddenly , you may have unpleasant symptoms such as agitation, confusion, tingling or electric shock feelings.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Encorafenib. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Entrectinib. Enzalutamide is predicted to decrease the exposure to Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Eribulin. Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Erythromycin. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Escitalopram. Etodolac increases the risk of gastrointestinal bleeding when given with Prednisolone.
Etoricoxib increases the risk of gastrointestinal bleeding when given with Prednisolone. Felbinac increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Flecainide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Fluconazole.
Flurbiprofen increases the risk of gastrointestinal bleeding when given with Prednisolone. Both Prednisolone and Formoterol can increase the risk of hypokalaemia. Fosamprenavir is predicted to increase the exposure to Prednisolone.
Fosphenytoin is predicted to decrease the exposure to Prednisolone. Both Prednisolone and Furosemide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Glasdegib.
Prednisolone potentially opposes the effects of Glycerol phenylbutyrate. Manufacturer advises monitor ammonia concentrations. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Haloperidol. Herpes-zoster vaccine, live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose.
Both Prednisolone and Hydrochlorothiazide can increase the risk of hypokalaemia. Both Prednisolone and Hydroflumethiazide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxychloroquine. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxyzine. Ibuprofen increases the risk of gastrointestinal bleeding when given with Prednisolone.
Idelalisib is predicted to increase the exposure to Prednisolone. Both Prednisolone and Indacaterol can increase the risk of hypokalaemia. Both Prednisolone and Indapamide can increase the risk of hypokalaemia. Indometacin increases the risk of gastrointestinal bleeding when given with Prednisolone.
Influenza vaccine live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Inotuzumab ozogamicin. Prednisolone is predicted to decrease the efficacy of Ipilimumab. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Isoflurane.
Itraconazole is predicted to increase the exposure to Prednisolone. Ketoconazole is predicted to increase the exposure to Prednisolone. Ketoprofen increases the risk of gastrointestinal bleeding when given with Prednisolone.
Ketorolac increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Lapatinib. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Lenvatinib.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Levomepromazine. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Lithium. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Lofexidine. Lopinavir is predicted to increase the exposure to Prednisolone. Measles, mumps and rubella vaccine, live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose.
Mefenamic acid increases the risk of gastrointestinal bleeding when given with Prednisolone. Meloxicam increases the risk of gastrointestinal bleeding when given with Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Methadone. Both Prednisolone and Metolazone can increase the risk of hypokalaemia. Prednisolone is predicted to decrease the efficacy of Mifamurtide. Blood tests may be needed to check for unwanted effects. Do not start taking citalopram during the 14 days after you stop a MAO inhibitor. Wait 14 days after stopping citalopram before you start taking a MAO inhibitor.
If you take them together or do not the proper amount of time, you may develop confusion, agitation, restlessness, stomach or intestinal symptoms, a sudden high body temperature, an extremely high blood pressure, or severe seizures.
Using these medicines together can cause very serious heart problems. Citalopram may cause a serious condition called serotonin syndrome if taken together with some medicines. Check with your doctor first before taking any other medicines with citalopram. Citalopram may cause some teenagers and young adults to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed.
Some people may have trouble sleeping, get upset easily, have a big increase in energy, or start to act reckless. If you or your caregiver notice any of these unwanted effects, tell your doctor right away. Let the doctor know if you or anyone in your family has bipolar disorder manic-depressive or has tried to commit suicide. Contact your doctor right away if you have any changes to your heart rhythm. You might feel dizzy or faint, or you might have a fast, pounding, or irregular heartbeat.
Make sure your doctor knows if you or anyone in your family has ever had a heart rhythm problem including QT prolongation or slow heartbeat. Do not suddenly stop taking this medicine without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This will decrease the chance of having withdrawal symptoms such as agitation, breathing problems, chest pain, confusion, diarrhea, dizziness or lightheadedness, fast heartbeat, headache, increased sweating, muscle pain, nausea, restlessness, runny nose, trouble in sleeping, trembling or shaking, unusual tiredness or weakness, vision changes, or vomiting.
This medicine may increase your risk for bleeding problems. This medicine may cause hyponatremia low sodium in the blood. This is more common in elderly patients, those who are taking diuretic medicines for high blood pressure, or those who have decreased amounts of fluid in the body due to severe diarrhea or vomiting.
Check with your doctor right away if you have confusion, headache, memory problems, trouble concentrating, weakness, or feel unsteady when standing. This medicine may cause some people to become drowsy, have trouble thinking, or to have problems with movement.
Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert or well-coordinated. Your doctor may want to monitor your child's weight and height, because this medicine may cause decreased appetite and weight loss in children.
Drug interactions are reported among people who take Celexa and Prednisone. Common interactions include drug ineffective among females and pain among males. The phase IV clinical study analyzes what interactions people who take Celexa and Prednisone have.
You can use the study as a second opinion to make health care decisions. With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. Prednisone has active ingredients of prednisone.
It is often used in rheumatoid arthritis. You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
The study uses data from the FDA. It is based on citalopram hydrobromide and prednisone the active ingredients of Celexa and Prednisone, respectivelyand Celexa and Prednisone the brand names. Other drugs that have the same active ingredients e. Dosage of drugs is not considered in the study. With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials.
We study millions of patients and 5, more each day. Our analysis results are available to researchers, health care professionals, patients testimonialsand software developers open API. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship.
Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect.
The use of the eHealthMe site and its content is at your own risk. If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date. All rights reserved. Use of this site constitutes acceptance of eHealthMe.
Toggle navigation eHealth Me. Home Analysis Celexa Prednisone. What is Celexa? What is Prednisone? Some reports may have incomplete information. Who is eHealthMe?
Using predniSONE together with celecoxib may increase the risk of side effects in the gastrointestinal tract such as inflammation, bleeding, ulceration. Drug Interactions. Although certain medicines should not be used together at all, in other cases two different medicines may be used together. Minimal data are available on the interaction of corticosteroids with citalopram or placebo with some concurrently receiving prednisone. Prednisolone is predicted to cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with Citalopram. Manufacturer makes no. WebMD provides information about common drug or vitamin interactions for Prednisone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Sildenafil. Some people may have trouble sleeping, get upset easily, have a big increase in energy, or start to act reckless. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Vinflunine. Manufacturer advises use with caution or avoid. Manufacturer makes no recommendation.Currently viewing BNF. View prednisolone drug monograph. Interactions do not generally apply to corticosteroids used for topical action including inhalation unless specified. Prednisolone has the following interaction information:. Severe interactions are highlighted with a red marker.
Find out more about BNF interactions information. Aceclofenac increases the risk of gastrointestinal bleeding when given with Prednisolone. Manufacturer advises caution. Prednisolone is predicted to increase the effects of Acenocoumarol. Manufacturer advises monitor INR. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Amifampridine.
Manufacturer makes no recommendation. Both Prednisolone and Aminophylline can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Amiodarone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Amisulpride. Both Prednisolone and Amphotericin B can increase the risk of hypokalaemia.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Anagrelide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Apalutamide. Apalutamide is predicted to decrease the exposure to Prednisolone.
Manufacturer advises monitor and adjust dose. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Apomorphine. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Arsenic trioxide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Artemether. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Artenimol.
Prednisolone is predicted to decrease the concentration of Aspirin high-dose and Aspirin high-dose increases the risk of gastrointestinal bleeding when given with Prednisolone. Atazanavir is predicted to increase the exposure to Prednisolone. Manufacturer advises avoid or monitor adverse effects. Prednisolone is predicted to decrease the efficacy of Atezolizumab. Manufacturer advises use with caution or avoid. Prednisolone is predicted to decrease the effects of Atracurium.
Both Prednisolone and Bambuterol can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Bedaquiline. Both Prednisolone and Bendroflumethiazide can increase the risk of hypokalaemia. Benzydamine increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Bosutinib.
Bromfenac increases the risk of gastrointestinal bleeding when given with Prednisolone. Both Prednisolone and Bumetanide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Cabozantinib. Carbamazepine is predicted to decrease the exposure to Prednisolone.
Celecoxib increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Ceritinib.
Both Prednisolone and Chlorothiazide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Chlorpromazine. Both Prednisolone and Chlortalidone can increase the risk of hypokalaemia.
Prednisolone is predicted to decrease the concentration of Choline salicylate. Prednisolone is predicted to decrease the effects of Cisatracurium. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Citalopram. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Clarithromycin. Clarithromycin is predicted to increase the exposure to Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Clomipramine. Cobicistat is predicted to increase the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Crizotinib.
Darunavir is predicted to increase the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Dasatinib. Prednisolone is predicted to increase the risk of gastrointestinal bleeding when given with Deferasirox.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Delamanid. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Desflurane.
Dexketoprofen increases the risk of gastrointestinal bleeding when given with Prednisolone. Diclofenac increases the risk of gastrointestinal bleeding when given with Prednisolone.
Prednisolone is predicted to increase the risk of Digoxin toxicity when given with Digoxin. Prednisolone is predicted to increase the risk of immunosuppression when given with Dinutuximab.
Manufacturer advises avoid except in life-threatening situations. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Disopyramide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Dronedarone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Droperidol. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Efavirenz. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Encorafenib.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Entrectinib. Enzalutamide is predicted to decrease the exposure to Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Eribulin. Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with Prednisolone.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Erythromycin. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Escitalopram. Etodolac increases the risk of gastrointestinal bleeding when given with Prednisolone. Etoricoxib increases the risk of gastrointestinal bleeding when given with Prednisolone.
Felbinac increases the risk of gastrointestinal bleeding when given with Prednisolone. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Flecainide. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Fluconazole.
Flurbiprofen increases the risk of gastrointestinal bleeding when given with Prednisolone. Both Prednisolone and Formoterol can increase the risk of hypokalaemia. Fosamprenavir is predicted to increase the exposure to Prednisolone.
Fosphenytoin is predicted to decrease the exposure to Prednisolone. Both Prednisolone and Furosemide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Glasdegib. Prednisolone potentially opposes the effects of Glycerol phenylbutyrate. Manufacturer advises monitor ammonia concentrations.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Haloperidol. Herpes-zoster vaccine, live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose. Both Prednisolone and Hydrochlorothiazide can increase the risk of hypokalaemia.
Both Prednisolone and Hydroflumethiazide can increase the risk of hypokalaemia. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxychloroquine.
Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Hydroxyzine. Ibuprofen increases the risk of gastrointestinal bleeding when given with Prednisolone.
Idelalisib is predicted to increase the exposure to Prednisolone. Both Prednisolone and Indacaterol can increase the risk of hypokalaemia. Both Prednisolone and Indapamide can increase the risk of hypokalaemia. Indometacin increases the risk of gastrointestinal bleeding when given with Prednisolone. Influenza vaccine live is predicted to increase the risk of generalised infection possibly life-threatening when given with Prednisolone high-dose. Prednisolone is predicted to cause hypokalaemia potentially increasing the risk of torsade de pointes when given with Inotuzumab ozogamicin.
Comments
Post a Comment